Where are the primary sources for facts about Salspera, Inc. and Saltikva?

Primary sources for Salspera, Inc. and Saltikva are the SEC EDGAR filings (CIK 0002084032), the ClinicalTrials.gov records NCT04589234 ↗ and NCT01099631 ↗, the Phase 2 paper (PubMed 41591505 ↗), the Phase 1 paper (PubMed 32554977 ↗), the FDA Orphan Drug Designation database entries and the granted US Patents 11,576,936 and 12,090,179. SEC filings, the registry text and the company's own papers are company-authored, so their claims are company-stated.

Last reviewed 2026-11-04
All questions in this categoryAll 65 questions